{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:24:58Z","timestamp":1781018698651,"version":"3.54.1"},"reference-count":23,"publisher":"Zhejiang University Press","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1631\/jzus.b2000449","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T09:10:36Z","timestamp":1613639436000},"page":"156-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database","\u4e0e\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u76f8\u5173\u7684\u80c3\u80a0\u9053\u6bd2\u6027: \u5229\u7528 WHO \u836f\u7269\u4e0d\u826f\u53cd\u5e94\u6570\u636e\u5e93 VigiBase \u8fdb\u884c\u7684\u4e0d\u6210\u6bd4\u4f8b\u5206\u6790"],"prefix":"10.1631","volume":"22","author":[{"given":"Sifu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanta","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-730X","authenticated-orcid":false,"given":"Xiahong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"496_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-3-030-41008-7_12","volume-title":"Immunotherapy","author":"H Abu-Sbeih","year":"2020","unstructured":"Abu-Sbeih H, Wang YH, 2020. Gastrointestinal tract adverse events. In: Naing A, Hajjar J (Eds.), Immunotherapy. Springer, Cham, p.247\u2013253. https:\/\/doi.org\/10.1007\/978-3-030-41008-7_12"},{"key":"496_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","volume":"6","author":"MZ Afzal","year":"2018","unstructured":"Afzal MZ, Mercado RR, Shirai K, 2018. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer, 6:64. https:\/\/doi.org\/10.1186\/s40425-018-0375-1","journal-title":"J Immunother Cancer"},{"key":"496_CR3","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, et al., 2018. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ, 360:k793. https:\/\/doi.org\/10.1136\/bmj.k793","journal-title":"BMJ"},{"issue":"3","key":"496_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.12998\/wjcc.v8.i3.552","volume":"8","author":"JH Cho","year":"2020","unstructured":"Cho JH, Choi JH, 2020. Cytomegalovirus ileo-pancolitis presenting as toxic megacolon in an immunocompetent patient: a case report. World J Clin Cases, 8(3):552\u2013559. https:\/\/doi.org\/10.12998\/wjcc.v8.i3.552","journal-title":"World J Clin Cases"},{"key":"496_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2018.10.006","volume":"106","author":"A de Malet","year":"2019","unstructured":"de Malet A, Antoni G, Collins M, et al., 2019. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer, 106:106\u2013114. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.006","journal-title":"Eur J Cancer"},{"issue":"6","key":"496_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, et al., 2018. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol, 29(6):1437\u20131444. https:\/\/doi.org\/10.1093\/annonc\/mdy103","journal-title":"Ann Oncol"},{"issue":"15","key":"496_CR7","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, et al., 2019. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res, 25(15):4592\u20134602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1538","journal-title":"Clin Cancer Res"},{"key":"496_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","volume":"19","author":"LH Gu","year":"2019","unstructured":"Gu LH, Khadaroo PA, Su H, et al., 2019. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1\/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer, 19:559. https:\/\/doi.org\/10.1186\/s12885-019-5785-z","journal-title":"BMC Cancer"},{"issue":"Suppl_4","key":"496_CR9","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al., 2017. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28(Suppl_4):iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"issue":"7","key":"496_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00063-015-0076-1","volume":"110","author":"M Leppkes","year":"2015","unstructured":"Leppkes M, Ganslmayer M, Strau\u00df R, et al., 2015. Das toxic megacolon. Med Klin Intensivmed Notfmed, 110(7):500\u2013505. https:\/\/doi.org\/10.1007\/s00063-015-0076-1","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"5","key":"496_CR11","doi-asserted-by":"publisher","first-page":"150932","DOI":"10.1016\/j.soncn.2019.08.011","volume":"35","author":"K Madden","year":"2019","unstructured":"Madden K, Kasler MK, 2019. Immune checkpoint inhibitors in lung cancer and melanoma. Semin Oncol Nurs, 35(5):150932. https:\/\/doi.org\/10.1016\/j.soncn.2019.08.011","journal-title":"Semin Oncol Nurs"},{"issue":"24","key":"496_CR12","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1158\/1078-0432.CCR-17-3108","volume":"24","author":"A Rodriguez-Vida","year":"2018","unstructured":"Rodriguez-Vida A, Perez-Gracia JL, Bellmunt J, 2018. Immunotherapy combinations and sequences in urothelial cancer: facts and hopes. Clin Cancer Res, 24(24):6115\u20136124. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3108","journal-title":"Clin Cancer Res"},{"issue":"2","key":"496_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, et al., 2020. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol, 72(2):320\u2013341. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.021","journal-title":"J Hepatol"},{"issue":"9","key":"496_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1631\/jzus.B2000253","volume":"21","author":"M Song","year":"2020","unstructured":"Song M, Li ZL, Zhou YJ, et al., 2020. Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(9):749\u2013751. https:\/\/doi.org\/10.1631\/jzus.B2000253","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"issue":"3","key":"496_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/CJI.0000000000000213","volume":"41","author":"P Tandon","year":"2018","unstructured":"Tandon P, Bourassa-Blanchette S, Bishay K, et al., 2018. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother, 41(3):101\u2013108. https:\/\/doi.org\/10.1097\/CJI.0000000000000213","journal-title":"J Immunother"},{"issue":"10","key":"496_CR16","doi-asserted-by":"publisher","first-page":"e1344805","DOI":"10.1080\/2162402X.2017.1344805","volume":"6","author":"DY Wang","year":"2017","unstructured":"Wang DY, Ye F, Zhao SL, et al., 2017. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology, 6(10):e1344805. https:\/\/doi.org\/10.1080\/2162402X.2017.1344805","journal-title":"Oncoimmunology"},{"issue":"12","key":"496_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al., 2018. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"14","key":"496_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al., 2017. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med, 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"496_CR19","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, et al., 2018. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ, 363:k4226. https:\/\/doi.org\/10.1136\/bmj.k4226","journal-title":"BMJ"},{"issue":"1","key":"496_CR20","first-page":"123","volume":"12","author":"ZH Yuan","year":"2019","unstructured":"Yuan ZH, Yang HK, Wei YM, 2019. Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. Int J Clin Exp Pathol, 12(1): 123\u2013132.","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"496_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1631\/jzus.B2000172","volume":"21","author":"J Zhang","year":"2020","unstructured":"Zhang J, Li HH, Chen YF, et al., 2020. Microencapsulation of immunoglobulin Y: optimization with response surface morphology and controlled release during simulated gastrointestinal digestion. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(8):611\u2013627. https:\/\/doi.org\/10.1631\/jzus.B2000172","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"issue":"2","key":"496_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/his.13963","volume":"76","author":"ML Zhang","year":"2020","unstructured":"Zhang ML, Neyaz A, Patil D, et al., 2020. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology, 76(2):233\u2013243. https:\/\/doi.org\/10.1111\/his.13963","journal-title":"Histopathology"},{"issue":"9","key":"496_CR23","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S0149-2918(01)80121-1","volume":"23","author":"SZ Zhao","year":"2001","unstructured":"Zhao SZ, Reynolds MW, Lefkowith J, et al., 2001. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization\/Uppsala Monitoring Centre safety database. Clin Ther, 23(9):1478\u20131491. https:\/\/doi.org\/10.1016\/s0149-2918(01)80121-1","journal-title":"Clin Ther"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2000449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2000449\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2000449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:34:15Z","timestamp":1744151655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["496"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2000449","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sifu HUANG, Xuefeng BAI, Taiyong FANG, Yanta GUO, Kainan ZHENG, and Xiahong LIN declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}